Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo
Recordati will acquire global rights to Enjaymo from Sanofi for $825M, significantly boosting its rare disease portfolio. This strategic acquisition highlights Recordati's commitment to expanding its offerings in the healthcare sector. The deal encompasses milestone payments that could yield further benefits, positioning both companies favorably within the biotech landscape. Expected closure of the transaction is set for the end of 2024.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.